Nuvation Bio, Inc.(NUVB)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

NUVB Nuvation Bio, Inc.

已收盘 01-12 16:00:00 EST

6.46

-1.58

-19.65%

盘后6.55

+0.09+1.39%

19:58 EST

最高7.70	最低6.32	成交量1,560万
今开7.69	昨收8.04	日振幅17.22%
总市值22.15亿	流通市值14.93亿	总股本3.43亿
成交额1.04亿	换手率6.75%	流通股本2.31亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"NUVB","market":"US","secType":"STK","nameCN":"Nuvation Bio, Inc.","latestPrice":6.46,"timestamp":1768251600000,"preClose":8.04,"halted":0,"volume":15595665,"hourTrading":{"tag":"盘后","latestPrice":6.55,"preClose":6.46,"latestTime":"19:58 EST","volume":77035,"amount":503253.7757,"timestamp":1768265906151},"delay":0,"floatShares":231046340,"shares":342833433,"eps":-0.640012,"marketStatus":"已收盘","change":-1.58,"latestTime":"01-12 16:00:00 EST","open":7.69,"high":7.6998,"low":6.315,"amount":104221747.80946949,"amplitude":0.172239,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-0.640012,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1768294800000},"marketStatusCode":5,"adr":0,"exchange":"NYSE","adjPreClose":8.04,"preHourTrading":{"tag":"盘前","latestPrice":7.63,"preClose":8.04,"latestTime":"09:29 EST","volume":76126,"amount":599085.9807632,"timestamp":1768228199164},"postHourTrading":{"tag":"盘后","latestPrice":6.55,"preClose":6.46,"latestTime":"19:58 EST","volume":77035,"amount":503253.7757,"timestamp":1768265906151},"volumeRatio":3.045231,"optionData":{"bulkOrders":[{"symbol":"NUVB","call":true,"expireDate":1773979200000,"strike":"5.0","timestamp":1768241204491,"price":1.8,"volume":5000,"amount":900000,"type":"-"}]},"impliedVol":1.6614,"impliedVolPercentile":0.8486},"requestUrl":"/m/hq/s/NUVB","defaultTab":"news","newsList":[{"id":"1197728511","title":"Nuvation Bio公司：晚期ROS1+非小细胞肺癌治疗药物上市许可申请预计2026年上半年在欧洲提交","url":"https://stock-news.laohu8.com/highlight/detail?id=1197728511","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1197728511?lang=zh_cn&edition=full","pubTime":"2026-01-12 20:33","pubTimestamp":1768221217,"startTime":"0","endTime":"0","summary":"Nuvation Bio公司宣布，其针对晚期ROS1阳性非小细胞肺癌（NSCLC）的治疗药物上市许可申请（MAA），预计将于2026年上半年在欧洲提交。这一进展标志着公司在肿瘤治疗领域的重要里程碑，有望为特定肺癌患者提供新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NUVB","BK4007"],"gpt_icon":0},{"id":"1155392565","title":"信达生物宣布七种创新药物入选中国国家医保药品目录，包括Tyvyt新适应症和Sycume","url":"https://stock-news.laohu8.com/highlight/detail?id=1155392565","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1155392565?lang=zh_cn&edition=full","pubTime":"2025-12-07 11:41","pubTimestamp":1765078874,"startTime":"0","endTime":"0","summary":"信达生物宣布七种创新药物入选中国国家医保药品目录，包括Tyvyt新适应症和Sycume。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2097828631.EUR","NUVB","LU2097828714.EUR","BK1161","LU2097828474.EUR","LU2097828557.USD","LU2328871848.SGD","LU2097828805.USD","BK1589","LU2488822045.USD","LU0455707207.USD","LU0502904849.HKD","LU2242644610.SGD","HK0000165453.HKD","01801","BK1583","LU1969619763.USD","BK4007"],"gpt_icon":0},{"id":"1169045020","title":"Nuvation Bio公布Safusidenib二期临床试验积极结果，用于治疗2级Idh1突变胶质瘤","url":"https://stock-news.laohu8.com/highlight/detail?id=1169045020","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1169045020?lang=zh_cn&edition=full","pubTime":"2025-12-03 21:01","pubTimestamp":1764766896,"startTime":"0","endTime":"0","summary":"Nuvation Bio公布了关于Safusidenib用于治疗2级Idh1突变胶质瘤的二期临床试验positive结果。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NUVB"],"gpt_icon":0},{"id":"1174114198","title":"Nuvation Bio：原本为Nuv-1511预算的资源将转移至其他研发分子及DDC候选药物的开发","url":"https://stock-news.laohu8.com/highlight/detail?id=1174114198","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1174114198?lang=zh_cn&edition=full","pubTime":"2025-11-26 21:38","pubTimestamp":1764164290,"startTime":"0","endTime":"0","summary":"Nuvation Bio：原本为Nuv-1511预算的资源将转移至其他研发分子及DDC候选药物的开发","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NUVB","BK4007"],"gpt_icon":0},{"id":"1126003260","title":"Nuvation Bio, Inc.：因各组疗效一致性不足而作出此项决定","url":"https://stock-news.laohu8.com/highlight/detail?id=1126003260","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1126003260?lang=zh_cn&edition=full","pubTime":"2025-11-26 21:38","pubTimestamp":1764164288,"startTime":"0","endTime":"0","summary":"Nuvation Bio, Inc.：因各组疗效一致性不足而作出此项决定","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NUVB","BK4007"],"gpt_icon":0},{"id":"1175640480","title":"修正-Nuvation Bio第三季度收入为1,310万美元，超出Ibes预估的680万美元（修正金额）","url":"https://stock-news.laohu8.com/highlight/detail?id=1175640480","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1175640480?lang=zh_cn&edition=full","pubTime":"2025-11-04 07:05","pubTimestamp":1762211109,"startTime":"0","endTime":"0","summary":"修正-Nuvation Bio第三季度收入为1,310万美元，超出Ibes预估的680万美元（修正金额）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NUVB"],"gpt_icon":0},{"id":"1195111354","title":"Nuvation Bio第三季度每股收益为-0.16美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1195111354","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1195111354?lang=zh_cn&edition=full","pubTime":"2025-11-04 05:23","pubTimestamp":1762204996,"startTime":"0","endTime":"0","summary":"11月3日——Nuvation Bio第三季度收入为772.3万美元，超过IBES预估的680万美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NUVB","BK4007"],"gpt_icon":0},{"id":"1160137364","title":"Nuvation Bio开始全球随机研究，首位患者接受Safusidenib用于高等级Idh1突变胶质瘤的维持治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1160137364","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1160137364?lang=zh_cn&edition=full","pubTime":"2025-10-23 19:32","pubTimestamp":1761219133,"startTime":"0","endTime":"0","summary":"Nuvation Bio开始全球随机研究，首位患者接受Safusidenib用于高等级Idh1突变胶质瘤的维持治疗","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NUVB"],"gpt_icon":0},{"id":"1161573203","title":"Nuvation Bio公司：在日本首次确定报销价格后将获得2500万美元里程碑付款","url":"https://stock-news.laohu8.com/highlight/detail?id=1161573203","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1161573203?lang=zh_cn&edition=full","pubTime":"2025-09-19 19:32","pubTimestamp":1758281542,"startTime":"0","endTime":"0","summary":"Nuvation Bio公司宣布，一旦在日本首次确定其产品的报销价格，公司将获得2500万美元的里程碑付款。这一重要的财务里程碑标志着该公司在日本市场的重大进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NUVB"],"gpt_icon":0},{"id":"1122972923","title":"Nuvation Bio获得日本厚生劳动省批准，Ibtrozitm药物可用于治疗晚期ROS1阳性非小细胞肺癌患者","url":"https://stock-news.laohu8.com/highlight/detail?id=1122972923","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1122972923?lang=zh_cn&edition=full","pubTime":"2025-09-19 19:31","pubTimestamp":1758281491,"startTime":"0","endTime":"0","summary":"Nuvation Bio已获得日本厚生劳动省的批准，其药物Ibtrozitm可用于治疗患有晚期ROS1阳性非小细胞肺癌的患者。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NUVB","BK4007"],"gpt_icon":0},{"id":"2568079286","title":"Nuvation Bio Inc.盘中异动 股价大涨5.06%报3.43美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2568079286","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2568079286?lang=zh_cn&edition=full","pubTime":"2025-09-18 21:47","pubTimestamp":1758203221,"startTime":"0","endTime":"0","summary":"北京时间2025年09月18日21时47分，Nuvation Bio Inc.股票出现异动，股价急速上涨5.06%。截至发稿，该股报3.43美元/股，成交量25.7973万股，换手率0.08%，振幅2.70%。Nuvation Bio Inc.股票所在的生物技术行业中，整体涨幅为0.52%。其相关个股中，89Bio, Inc.、Aptevo Therapeutics Inc.、Psyence Biomedical Ltd.涨幅较大，Aptevo Therapeutics Inc.、Psyence Biomedical Ltd.、Biocardia, Inc.较为活跃，换手率分别为2063.08%、904.46%、269.86%，振幅较大的相关个股有Psyence Biomedical Ltd C/Wts 25/01/2029、Psyence Biomedical Ltd.、Replimune Group, Inc.，振幅分别为52.69%、31.72%、22.59%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025091821470295369c1a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025091821470295369c1a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","NUVB"],"gpt_icon":0},{"id":"1100554602","title":"Nuvation Bio在2025年世界肺癌大会上公布Ibtrozi™(Taletrectinib)治疗晚期ROS1阳性非小细胞肺癌关键临床研究的最新数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1100554602","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1100554602?lang=zh_cn&edition=full","pubTime":"2025-09-07 18:00","pubTimestamp":1757239216,"startTime":"0","endTime":"0","summary":"Nuvation Bio在2025年世界肺癌大会上公布Ibtrozi™(Taletrectinib)治疗晚期ROS1阳性非小细胞肺癌关键临床研究的最新数据","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NUVB"],"gpt_icon":0},{"id":"2558666294","title":"Nuvation Bio Inc.盘中异动 急速跳水5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2558666294","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2558666294?lang=zh_cn&edition=full","pubTime":"2025-08-12 01:41","pubTimestamp":1754934076,"startTime":"0","endTime":"0","summary":"北京时间2025年08月12日01时41分，Nuvation Bio Inc.股票出现异动，股价急速下跌5.00%。截至发稿，该股报2.19美元/股，成交量219.844万股，换手率0.64%，振幅6.09%。Nuvation Bio Inc.股票所在的生物技术行业中，整体跌幅为0.34%。其相关个股中，Equillium, Inc.、Entero Therapeutics Inc.、Bioxcel Therapeutics, Inc.涨幅较大，Entero Therapeutics Inc.、Equillium, Inc.、Bioxcel Therapeutics, Inc.较为活跃，换手率分别为6054.86%、613.88%、328.84%，振幅较大的相关个股有Equillium, Inc.、Entero Therapeutics Inc.、Jyong Biotech Ltd.，振幅分别为84.05%、74.27%、62.69%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250812014117a6e0037e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250812014117a6e0037e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","NUVB"],"gpt_icon":0},{"id":"1113443519","title":"异动解读 | Nuvation Bio盘中大涨5.13%，Q2财报显示亏损大幅收窄","url":"https://stock-news.laohu8.com/highlight/detail?id=1113443519","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1113443519?lang=zh_cn&edition=full","pubTime":"2025-08-08 21:35","pubTimestamp":1754660142,"startTime":"0","endTime":"0","summary":"生物制药公司Nuvation Bio, Inc. 今日盘中大涨5.13%，引发投资者关注。这一显著涨幅与公司最新发布的第二季度财报密切相关。根据公司发布的财报显示，Nuvation Bio 2025财年前六个月的累计收入达到791.70万美元，相比去年同期的143.50万美元大幅增长451.71%。更引人注目的是，公司的净亏损同比大幅收窄。作为一家专注于开发创新肿瘤治疗药物的生物制药公司，Nuvation Bio的研发进展和商业化前景受到市场密切关注。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["NUVB"],"gpt_icon":0},{"id":"1145903047","title":"异动解读 | Nuvation Bio盘中大涨5.13%，Q2财报业绩大幅改善","url":"https://stock-news.laohu8.com/highlight/detail?id=1145903047","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1145903047?lang=zh_cn&edition=full","pubTime":"2025-08-08 21:35","pubTimestamp":1754660131,"startTime":"0","endTime":"0","summary":"生物制药公司Nuvation Bio, Inc.今日盘中大涨5.13%，引起投资者广泛关注。根据公司最新发布的2025财年第二季度财报，Nuvation Bio在上半年实现累计收入791.70万美元，较去年同期的143.50万美元大幅增长451.71%。每股基本亏损也从去年同期的2.06美元改善至0.33美元。Nuvation Bio成立于2020年，专注于开发创新的肿瘤治疗药物，以解决癌症治疗领域的重大未满足需求。此次财报显示的业绩大幅改善，反映出公司在研发和商业化方面取得了显著进展，这可能是推动股价上涨的主要原因。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["NUVB"],"gpt_icon":0},{"id":"1105563439","title":"异动解读 | Nuvation Bio股价盘中大涨5.02%，强劲财报及肿瘤治疗进展提振信心","url":"https://stock-news.laohu8.com/highlight/detail?id=1105563439","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1105563439?lang=zh_cn&edition=full","pubTime":"2025-08-07 22:49","pubTimestamp":1754578147,"startTime":"0","endTime":"0","summary":"生物科技公司Nuvation Bio, Inc.今日盘中大涨5.02%，引发市场关注。这一显著涨幅主要受到公司最新财报超预期及重要肿瘤治疗进展的推动。根据Nuvation Bio发布的第二季度财报，公司营收达到123.8万美元，远超分析师预期的35.71万美元。与此同时，Nuvation Bio发布的企业演示文稿进一步提振了投资者信心。这些进展表明Nuvation Bio在肿瘤治疗领域具有强大的创新能力和市场潜力，为公司未来的增长奠定了坚实基础。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["NUVB"],"gpt_icon":0},{"id":"1184883664","title":"异动解读 | Nuvation Bio盘中大跌5.32%，Q2亏损扩大超预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1184883664","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1184883664?lang=zh_cn&edition=full","pubTime":"2025-08-07 21:59","pubTimestamp":1754575170,"startTime":"0","endTime":"0","summary":"生物制药公司Nuvation Bio今日盘中大跌5.32%，投资者对其最新发布的第二季度财报反应强烈。虽然Nuvation Bio的收入表现优于预期，但巨额亏损和高企的运营支出似乎打击了投资者信心。然而，市场似乎对公司短期内实现盈利的能力产生了疑虑，这可能是导致股价大幅下跌的主要原因。投资者将密切关注公司未来的现金消耗率和产品管线进展，以评估其长期发展前景。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["NUVB"],"gpt_icon":0},{"id":"2557130971","title":"Nuvation Bio Inc.盘中异动 快速下挫5.06%报2.25美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2557130971","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557130971?lang=zh_cn&edition=full","pubTime":"2025-08-07 01:59","pubTimestamp":1754503167,"startTime":"0","endTime":"0","summary":"北京时间2025年08月07日01时59分，Nuvation Bio Inc.股票出现异动，股价大幅下跌5.06%。截至发稿，该股报2.25美元/股，成交量170.559万股，换手率0.50%，振幅3.80%。Nuvation Bio Inc.股票所在的生物技术行业中，整体跌幅为0.41%。其相关个股中，Biomx Inc.、Rigel Pharmaceuticals, Inc.、Avidity Biosciences, Inc.涨幅较大，Bioxcel Therapeutics, Inc.、Biomx Inc.、Tnf Pharmaceuticals, Inc.较为活跃，换手率分别为717.84%、562.33%、99.18%，振幅较大的相关个股有Briacell Therapeutics Corp C/Wts 26/02/2026、Conduit Pharmaceuticals Inc C/Wts 22/09/2028、Cingulate Inc C/Wts 10/12/2026 ，振幅分别为57.18%、48.52%、47.87%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202508070159289737e932&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202508070159289737e932&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NUVB","BK4007"],"gpt_icon":0},{"id":"2556814671","title":"Nuvation Bio Inc.盘中异动 早盘股价大跌5.00%报2.24美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2556814671","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2556814671?lang=zh_cn&edition=full","pubTime":"2025-08-01 21:47","pubTimestamp":1754056023,"startTime":"0","endTime":"0","summary":"北京时间2025年08月01日21时47分，Nuvation Bio Inc.股票出现波动，股价快速跳水5.00%。截至发稿，该股报2.24美元/股，成交量50.2287万股，换手率0.15%，振幅3.01%。Nuvation Bio Inc.股票所在的生物技术行业中，整体涨幅为0.26%。其相关个股中，天境生物、4D Molecular Therapeutics, Inc.、Bioxcel Therapeutics, Inc.涨幅较大，Bioxcel Therapeutics, Inc.、Salarius Pharmaceuticals, Inc.、Tnf Pharmaceuticals, Inc.较为活跃，换手率分别为917.98%、120.17%、108.98%，振幅较大的相关个股有Neurosense Therapeutics Ltd.、天境生物、Bioxcel Therapeutics, Inc.，振幅分别为29.12%、22.89%、22.14%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250801214703972d06cf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250801214703972d06cf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NUVB","BK4007"],"gpt_icon":0},{"id":"2554777264","title":"Nuvation Bio Inc.盘中异动 股价大涨5.20%","url":"https://stock-news.laohu8.com/highlight/detail?id=2554777264","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2554777264?lang=zh_cn&edition=full","pubTime":"2025-07-28 21:47","pubTimestamp":1753710432,"startTime":"0","endTime":"0","summary":"北京时间2025年07月28日21时47分，Nuvation Bio Inc.股票出现异动，股价急速拉升5.20%。截至发稿，该股报2.63美元/股，成交量71.4993万股，换手率0.21%，振幅4.40%。Nuvation Bio Inc.股票所在的生物技术行业中，整体涨幅为0.05%。其相关个股中，Celcuity Inc.、Aim Immunotech Inc.、Cervomed Inc.涨幅较大，Aim Immunotech Inc.、Tnf Pharmaceuticals, Inc.、Cervomed Inc.较为活跃，换手率分别为231.88%、118.65%、89.79%，振幅较大的相关个股有Aim Immunotech Inc.、Celcuity Inc.、Nrx Pharmaceuticals Inc C/Wts 24/05/2026 ，振幅分别为48.81%、37.76%、20.41%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250728214712a467df72&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250728214712a467df72&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","NUVB"],"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":-0.0629},{"period":"1month","weight":0.0255},{"period":"3month","weight":1.1497},{"period":"6month","weight":2.6545},{"period":"1year","weight":1.6711},{"period":"ytd","weight":-0.1027}],"compareEarnings":[{"period":"1week","weight":0.016},{"period":"1month","weight":0.0095},{"period":"3month","weight":0.0629},{"period":"6month","weight":0.113},{"period":"1year","weight":0.1774},{"period":"ytd","weight":0.0178}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Nuvation Bio is a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates. Nuvation Bio's proprietary portfolio includes six novel and mechanistically distinct oncology therapeutic product candidates, each targeting some of the most difficult-to-treat types of cancer. Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung , M.D., who previously founded Medivation, Inc., which brought to patients one of the world's leading prostate cancer medicines. Nuvation Bio has offices in New York and San Francisco .","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.047741},{"month":2,"riseRate":0.2,"avgChangeRate":-0.07924},{"month":3,"riseRate":0.6,"avgChangeRate":0.155399},{"month":4,"riseRate":0.4,"avgChangeRate":0.005292},{"month":5,"riseRate":0.6,"avgChangeRate":0.002702},{"month":6,"riseRate":0.2,"avgChangeRate":-0.090917},{"month":7,"riseRate":0.6,"avgChangeRate":0.065913},{"month":8,"riseRate":0.6,"avgChangeRate":0.013694},{"month":9,"riseRate":0.5,"avgChangeRate":-0.038205},{"month":10,"riseRate":0.166667,"avgChangeRate":-0.016548},{"month":11,"riseRate":0.5,"avgChangeRate":0.163132},{"month":12,"riseRate":0.666667,"avgChangeRate":0.061496}],"exchange":"NYSE","name":"Nuvation Bio, Inc.","nameEN":"Nuvation Bio, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Nuvation Bio, Inc.(NUVB)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Nuvation Bio, Inc.(NUVB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Nuvation Bio, Inc.,NUVB,Nuvation Bio, Inc.股票,Nuvation Bio, Inc.股票老虎,Nuvation Bio, Inc.股票老虎国际,Nuvation Bio, Inc.行情,Nuvation Bio, Inc.股票行情,Nuvation Bio, Inc.股价,Nuvation Bio, Inc.股市,Nuvation Bio, Inc.股票价格,Nuvation Bio, Inc.股票交易,Nuvation Bio, Inc.股票购买,Nuvation Bio, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Nuvation Bio, Inc.(NUVB)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Nuvation Bio, Inc.(NUVB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}